Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells

BackgroundLung cancer and pleural mesothelioma are two of the most deadly forms of cancer. The prognosis of lung cancer and mesothelioma is extremely poor due to limited treatment modalities and lack of understanding of the disease mechanisms. We have identified mesothelin as a potentially unique therapeutic target that as a specific advantage appears nonessential in most cell types. Mesothelin (MSLN), a plasma membrane differentiation antigen, is expressed at a high level in many human solid tumors, including 70% of lung cancer and nearly all mesotheliomas. However, the role of MSLN in the disease process and underlying mechanisms is largely unknown.MethodsShRNA knockdown and overexpression of MSLN were performed in human cancer cell lines and corresponding normal cells, respectively. Tumorigenic and metastatic effects of MSLN were examined by tumor sphere formation, migration, and invasion assays in vitro, as well as xenograft tumor assay in vivo. EMT and CSCs were detected by qPCR array, immunoblotting and flow cytometry.ResultsMSLN plays a key role in controlling epithelial-to-mesenchymal transition (EMT) and stem properties of human lung cancer and mesothelioma cells that control their tumorigenicity and metastatic potential. Firstly, MSLN was found to be highly upregulated in non-small cell lung cancer (NSCLC) patient tissues and in lung carcinoma and mesothelioma cell lines. Secondly, genetic knockdown of MSLN significantly reduced anchorage-independent cell growth, tumor sphere formation, cell adhesion, migration and invasion in vitro, as well as tumor formation and metastasis in vivo. Thirdly, ectopic overexpression of MSLN induced the malignant phenotype of non-cancerous cells, supporting its role as an oncogene. Finally, mechanistic studies revealed that knockdown of MSLN reversed EMT and attenuated stem cell properties, in addition to inhibiting tumor growth and metastasis.ConclusionsThese results indicate an essential role of MSLN in controlling EMT and stem cell properties of human lung cancer and mesothelioma cells. Since EMT is an important process in tumor progression and metastasis, and MSLN is nonessential in most normal tissue, our findings on MSLN may provide new insights into the disease mechanisms and may aid in the development of novel targeted therapy for lung cancer and mesothelioma.

[1]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[2]  W. Birchmeier,et al.  E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells , 1991, The Journal of cell biology.

[3]  I. Pastan,et al.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Sugarbaker,et al.  Multimodality management of malignant pleural mesothelioma. , 1998, Chest.

[5]  Z. Ye,et al.  Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[6]  I. Pastan,et al.  Mesothelin Is Not Required for Normal Mouse Development or Reproduction , 2000, Molecular and Cellular Biology.

[7]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[8]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[9]  M. Nieto,et al.  The Snail genes as inducers of cell movement and survival: implications in development and cancer , 2005, Development.

[10]  E. Lander,et al.  Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. , 2008, Cancer research.

[11]  F. Portillo,et al.  Transcriptional regulation of cell polarity in EMT and cancer , 2008, Oncogene.

[12]  N. Uehara,et al.  Mesothelin Promotes Anchorage-Independent Growth and Prevents Anoikis via Extracellular Signal-Regulated Kinase Signaling Pathway in Human Breast Cancer Cells , 2008, Molecular Cancer Research.

[13]  G. Berx,et al.  The cell-cell adhesion molecule E-cadherin , 2008, Cellular and Molecular Life Sciences.

[14]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[15]  Robert A. Weinberg,et al.  Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. , 2008, Developmental cell.

[16]  D. Sugarbaker.  Multimodality management of malignant pleural mesothelioma: introduction. , 2009, Seminars in thoracic and cardiovascular surgery.

[17]  Chien-Nan Lee,et al.  Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway. , 2009, The Biochemical journal.

[18]  Editors-in-Chief C. Nicot.  Molecular Cancer , 2009 .

[19]  R. Huang,et al.  Epithelial-Mesenchymal Transitions in Development and Disease , 2009, Cell.

[20]  R. Mansel,et al.  Loss of occludin leads to the progression of human breast cancer. , 2010, International journal of molecular medicine.

[21]  Kakajan Komurov,et al.  Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes , 2010, Proceedings of the National Academy of Sciences.

[22]  Xuefeng Lu,et al.  The tight junction protein, occludin, regulates the directional migration of epithelial cells. , 2010, Developmental cell.

[23]  S. Agelaki,et al.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients , 2011, Breast Cancer Research.

[24]  Q. Yao,et al.  Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression , 2011, Molecular Cancer.

[25]  Q. Yao,et al.  Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation. , 2010, Carcinogenesis.

[26]  M. Kitajima,et al.  Cooperation of Cancer Stem Cell Properties and Epithelial-Mesenchymal Transition in the Establishment of Breast Cancer Metastasis , 2010, Journal of oncology.

[27]  G. Sowa.  Novel Insights into the Role of Caveolin-2 in Cell- and Tissue-Specific Signaling and Function , 2011, Biochemistry research international.

[28]  V. Valero,et al.  Molecular Medicine in Practice Epithelial – Mesenchymal Transition and StemCell Markers in Patients with HER 2-Positive Metastatic Breast Cancer , 2012 .

[29]  Richard A. Woo,et al.  Inhibition of Mesothelin as a Novel Strategy for Targeting Cancer Cells , 2012, PloS one.

[30]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[31]  V. Valero,et al.  Epithelial–Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer , 2012, Molecular Cancer Therapeutics.

[32]  C. Sima,et al.  Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients , 2012, Clinical Cancer Research.

[33]  E. Je,et al.  The Role of Transcription Factor TWIST in Cancer Cells , 2013 .

[34]  Sridhar Ramaswamy,et al.  Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition , 2013, Science.

[35]  A. Yu,et al.  Claudins and the modulation of tight junction permeability. , 2013, Physiological reviews.

[36]  J. Lachuer,et al.  A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. , 2013, Cancer cell.

[37]  Shu-Yan Liu,et al.  High aldehyde dehydrogenase activity identifies cancer stem cells in human cervical cancer , 2013, Oncotarget.

[38]  D. Cui,et al.  Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. , 2013, International journal of oncology.

[39]  O. Gorbatyuk,et al.  The Molecular Chaperone GRP78/BiP as a Therapeutic Target for Neurodegenerative Disorders: A Mini Review. , 2013, Journal of genetic syndromes & gene therapy.

[40]  C. Sima,et al.  Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma , 2013, Clinical Cancer Research.

[41]  D. O'Shannessy,et al.  Folate Receptor Alpha, Mesothelin and Megakaryocyte Potentiating Factor as Potential Serum Markers of Chronic Kidney Disease , 2014, Biomarker insights.

[42]  Samy Lamouille,et al.  Molecular mechanisms of epithelial–mesenchymal transition , 2014, Nature Reviews Molecular Cell Biology.

[43]  D. Raha,et al.  The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. , 2014, Cancer research.

[44]  R. Barale,et al.  MSLN Gene Silencing Has an Anti-Malignant Effect on Cell Lines Overexpressing Mesothelin Deriving from Malignant Pleural Mesothelioma , 2014, PloS one.

[45]  L. Mishra,et al.  EMT, CTCs and CSCs in tumor relapse and drug-resistance , 2015, Oncotarget.

[46]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[47]  Michel Sadelain,et al.  Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. , 2016, Cancer discovery.

[48]  Nobutaka Mitsuda,et al.  The NAC transcription factor ANAC046 is a positive regulator of chlorophyll degradation and senescence in Arabidopsis leaves , 2016, Scientific Reports.

[49]  J. Marchal,et al.  Low adherent cancer cell subpopulations are enriched in tumorigenic and metastatic epithelial-to-mesenchymal transition-induced cancer stem-like cells , 2016, Scientific Reports.